Market Overview

The global animal health market size was valued at USD 38.99 Billion in 2024. It is projected to grow to USD 51.33 Billion by 2033, exhibiting a CAGR of 2.79% during the forecast period 2025-2033. Growth is primarily driven by rising pet adoption, increasing livestock production, heightened zoonotic disease concerns, and advances in veterinary medicine including biologics, pharmaceuticals, and diagnostics.

Study Assumption Years

• Base Year: 2024

• Historical Year/Period: 2019-2024

• Forecast Year/Period: 2025-2033

Animal Health Market Key Takeaways

• The animal health market size was valued at USD 38.99 Billion in 2024.

• The market is expected to grow with a CAGR of 2.79% during 2025-2033.

• Forecasted market size to reach USD 51.33 Billion by 2033.

• North America dominated the market with a 44.9% share in 2024 due to a large pet parent population and a significant livestock industry.

• Technological advancements and rising awareness of zoonotic diseases are key factors boosting market growth.

• Increasing veterinary visits for dermatological conditions in dogs drives demand, especially in the United States.

• The market experiences a shift towards preventive healthcare practices for both companion and commercial animals.

Sample Request Link: https://www.imarcgroup.com/animal-health-market/requestsample

Market Growth Factors

The animal health market is propelled by growing outbreaks of zoonotic infections encouraging investments in vaccines, diagnostics, and antimicrobial therapies. Governments worldwide are implementing stricter regulations and surveillance programs for zoonotic disease monitoring and prevention. Public awareness campaigns promote responsible pet ownership and vaccination practices, while the livestock industry adopts biosecurity measures to minimize disease outbreaks and comply with food safety standards. These efforts collectively enhance disease management and contribute significantly to market growth.

Technological advancements in veterinary diagnostics facilitate early detection and rapid responses to emerging zoonotic threats. Pharmaceutical companies are innovating novel therapeutics and biologics for effective animal disease control. Increased funding for veterinary research accelerates developments in zoonotic disease prevention and treatment solutions. The integration of digital technologies improves disease monitoring, outbreak predictions, and real-time data sharing. Collaborations between veterinary and human healthcare sectors strengthen 'One Health' initiatives, further driving market expansion.

In the United States, demand is boosted by heightened requirements for targeted and safe treatments in canine dermatology, driven by rising pet adoption and awareness of skin disorders. Advancements in veterinary pharmaceuticals have led to targeted biologics and safer topical therapies. FDA approval and launch of products like Zenrelia™ in 2024 offer effective options for managing canine dermatologic conditions. Expansion of veterinary telemedicine and diagnostic tool innovations facilitate quicker identification and remote consultations, enriching care access and supporting market growth.

Market Segmentation

By Animal Type:

• Commercial: Includes livestock and poultry reared primarily for commercial needs such as milk and meat. Farmers are focusing on maintaining health and productivity through preventive healthcare measures including vaccinations and disease management, driving demand for vaccines, pharmaceuticals, and hygiene solutions.

• Companion: Not explicitly covered in extracted data.

By Product Type:

• Pharmaceuticals: Dominates in 2024 with 57.0% share, addressing disease prevention and treatment needs for pets and farm animals. Veterinary pharmaceutical firms invest heavily in R&D to develop innovative, species-specific medications and controlled-release formulations.

• Biologicals: Not explicitly detailed in extracted data.

• Medicinal Feed Additives: Not explicitly detailed in extracted data.

• Diagnostics: Includes advanced platforms such as ECG devices for early disease detection (e.g., heart conditions in dogs), enhancing diagnosis and treatment efficacy.

Regional Insights

North America dominates the global animal health market with a 44.9% share in 2024. This dominance is driven by a large population of pet parents focused on companion animal health and a growing livestock industry sustaining commercial animal productivity. The region benefits from pharmaceutical innovations, strong government regulations promoting animal welfare and biosecurity, and initiatives supporting industry growth. The United States alone accounts for 86.50% of the North American market share, with 66% of households owning pets in 2024. Emphasis on ethical, green farming and food safety further propels demand for high-end health solutions.

Recent Developments & News

In February 2024, Merck Animal Health acquired Elanco Animal Health's aqua business outside the US and Canada for USD 1.3 billion, including medicine, vaccines, nutritional supplements, and manufacturing and research facilities. January 2025 saw Ceva Animal Health secure rights to use Touchlight's dbDNA technology for developing innovative DNA vaccines in the animal health sector. November 2024, MSD Animal Health (part of Merck & Co.) announced European Commission approval for BRAVECTO® TriUNO, a new chewable tablet targeting internal and external parasites in dogs. In October 2024, the Indian government launched a USD 25 million G20 Pandemic Fund to enhance livestock health coverage and pandemic response by August 2026.

Key Players

• Bayer

• Elanco

• Merck

• Merial

• Zoetis Inc.

• Biogenesis Bago

• Boehringer Ingelheim

• Ceva Sante Animale

• Heska

• Neogen

• Novartis

• Thermo Fisher Scientific

• Vetoquinol

• Virbac

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

👉Get Custom Market Research for Your Business👈

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302